Comparison of adjuvant emulsions for their safety and ability to enhance the antibody response in horses immunized with African snake venoms

Mauricio Arguedas a, Deibid Umaña a, Edwin Moscoso a, Armando García a, Carolina Pereira b, Andrés Sánchez a, Gina Durán a, Daniel Cordero a, Adriana Sánchez a, Álvaro Segura a, Mariángela Vargas a, María Herrera a, Mauren Villalta a, Aarón Gómez a, Catalina Salas b, Cecilia Díaz a, José María Gutiérrez a, Guillermo León a,*

⇑ Corresponding author at: Guillermo León, Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica.
E-mail address: guillermo.leon@ucr.ac.cr (G. León).

Article history:
Received 6 June 2022
Received in revised form 20 October 2022
Accepted 21 October 2022
Available online 25 October 2022

Keywords:
Adjuvant emulsions
Antivenom
Carbigen
Emulsigen-D
Freund adjuvants
Horse immunization
Montanide
Snake venom

Abstract
Adjuvant emulsions are widely used to enhance the antibody response in animals used as immunoglobulin source to produce snake antivenoms. We tested the performance of four commercial emulsion adjuvants (Montanide, Freund, Carbigen, and Emulsigen-D) and an experimental adjuvant (QH-769) in the antibody response of horses towards venoms of the African snakes Bitis arietans, Echis ocellatus, Dendroaspis polylepis, and Naja nigricollis. Montanide, Freund and Carbigen adjuvants generated the highest immune response but induced moderate/severe local lesions at the site of injection. In contrast, Emulsigen-D and QH-769 adjuvants generated the lowest immune response and low incidence of local lesions. No evidence of systemic alterations was observed in the horses immunized with any of the adjuvants. It is suggested that the use of Montanide or Freund-based emulsions in the first immunization steps, followed by the use of Emulsigen-D, QH-769 or similar adjuvants in the following injections, could result in a satisfactory immune response against snake venoms, while not inducing serious local deleterious effects.

© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Snake antivenoms are formulations of immunoglobulins, or immunoglobulin fragments, purified from the plasma of animals (mainly horses or sheep) immunized with snake venoms [1]. Owing to the ability of these immunoglobulins to bind venom toxins and neutralize their toxicity, antivenoms have been used for over a century for the medical treatment of snakebite envenomations [1].

Immunization of animals for antivenom production is carried out by the repeated injection of various doses of venoms from one or more venomous species, following a predefined immunization program. The amount of venom injected has to be low in order to prevent tissue damage or other manifestations of envenomation, but high enough to trigger the activation of the immune system to produce large quantities of anti-venom antibodies [2,3]. In horses, injections are normally applied by the subcutaneous (s.c.) route and generally contain between 0.5 and 5.0 mg of venom per injection, depending on the manufacturer [3].

The goal of immunization schemes is to generate a high level of neutralizing antibodies, so that antivenoms can be formulated at a high potency and low total protein content, thus rendering the products more effective and safer. Moreover, with high anti-venom antibody titers more vials of antivenom can be produced per plasma volume, reducing the relative weight of fixed costs, thus making the process more productive and efficient [4].

Generally, during immunization, venoms are mixed with adjuvant substances that enhance the antibody response of animals. Several studies have evaluated different adjuvants and immunization schemes for antivenom production [5–10], but more research is needed in this field. The adjuvants normally used in the production of antivenoms are mineral salts, polymers, or emulsions [2,3].

Emulsions are mixtures composed of two or more immiscible liquids whose interfaces are stabilized by surfactants to form heterogeneous systems of microdroplets of a discontinuous phase dispersed in a continuous dispersing phase [11]. Depending on how the phases are organized, emulsions can be: a) simple...
water-in-oil (w/o) emulsions, when an aqueous phase is dispersed in an oily phase; b) simple o/w emulsions, when an oily phase is dispersed in an aqueous phase; c) multiple w/o/w emulsions, when a simple w/o emulsion is dispersed in an aqueous phase; or d) multiple o/w/o emulsions, when a simple o/w emulsion is dispersed in an oily phase [11].

The adjuvant activity of emulsions operates by a complex mechanism that is not entirely understood. It has been suggested that it involves the ability of emulsions to form depots from where immunogens are slowly released, generating a sustained stimulus to the immune system [12]. Other researchers indicate that adjuvant activity of emulsions is due to their ability to induce apoptosis or necrosis in cells which respond by generating “danger” signals that trigger the immune response [13]. Thus, the explanation of how adjuvant emulsions operate remains controversial.

Several adjuvant emulsions are commercially available. Montanide ISA 50 V2 is composed of an injectable mineral oil, vegetable oleic acid and a mannitol derived emulsifier. Incomplete Freund adjuvant is composed of mineral oil and Arlacel A as emulsifier agent. Complete Freund adjuvant contains, in addition, heat-killed cells of Mycobacterium tuberculosis or M. butyricum. Caribigen is an emulsified suspension of Carbopol 934P. Emulsigen-D is an o/w adjuvant that contains dimethyl octadecyl ammonium bromide (DDA) incorporated into the emulsion. Technical sheets of these commercial products can be found in the web. In addition, QH-769 is a squalene-based formulation used to prepare w/o emulsions.

Previously, we used a mouse model to study the relationship between the physical characteristics of emulsions and their adjuvant activities on the antibody response towards the venom of the African viperid snake *Echis ocellatus* [5]. Now, we scaled up the model to horses and tested the performance of four commercial emulsion adjuvants (i.e., Montanide, Freund, Caribigen, and Emulsigen-D) and an experimental adjuvant (i.e., QH-769) in the antibody response towards venoms of the African snakes *E. ocellatus*, *Bitis arietans*, *Dendroaspis polylepis* and *Naja nigricollis*.

### 2. Materials and methods

All procedures carried out in this study meet the International Guiding Principles for Biomedical Research Involving Animals [14]. All procedures involving animals were approved by the Institutional Committee for the Care and Use of Laboratory Animals of Universidad de Costa Rica (approval code CICUA 202-2020).

#### 2.1. Snake venoms

Venoms of adult specimens of *B. arietans* (batch #322.061), *E. ocellatus* (batch #200.171), *D. polylepis* (batch #416.031) and *N. nigricollis* (batch #616.031) were purchased from Latoxan (Portes-dès-Valence, France). After collection, venoms were stabilized by lyophilization and stored at –40 °C. Solutions of venoms were prepared immediately before use.

#### 2.2. Immunologic adjuvants

The adjuvants used in this study were: Montanide ISA 50V2 (SEPPIC, Castres, France, batch 190301019150); Complete Freund (Sigma-Aldrich, St. Louis, MO, USA, batch SLCB8308); Caribigen (MVP Adjuvants, Teaneck, NJ, USA, batch F18123); Emulsigen-D (MVP Adjuvants, batch D01449) and QH-769 (IDRI, Seattle, WA, USA, experimental batch). All adjuvants were used according to the manufacturers’ instructions.

#### 2.3. Immunization of horses

Five groups of four Spanish horses (370–490 kg body weight) were immunized using periodic injections of immunogens composed of equal parts of venoms of *B. arietans*, *E. ocellatus*, *D. polylepis* and *N. nigricollis*, dissolved in 0.12 M NaCl, 0.04 M phosphates, pH 7.2 (PBS) and mixed with either Montanide, Freund, Caribigen, Emulsigen-D or QH-769 adjuvants. In each group of horses, the same adjuvant was used throughout the immunization in all injections. The immunogens were administered in a single injection site in the back of the horse by the s.c. route. Doses and schedule of injections are specified in Table 1. The total volume of each venom injection was 2 mL. Blood samples were collected from the jugular vein before the onset of immunization and at different times during immunization to determine hematological, plasma chemistry and immunological parameters. The clinical and physical status of the animals were constantly monitored throughout the procedure. The whole process was carried out under veterinary supervision.

#### 2.4. Body condition, hematological and plasma chemistry evaluation

Body condition score (BCS) of horses was determined by palpation and visual appraisal of the fat accumulation in anatomical areas such as behind the shoulders, over the ribs, along the neck, along the withers, the crease down back and the tailhead [15]. Scores range from 1 (extremely emaciated) to 9 (extremely fat), with an ideal range between 4 and 6. Lesions developed at the injection site were evaluated and classified according to their severity as explained in the Results and Discussion section. Hematological analyses (i.e., erythrocyte, leukocyte and platelet counts, and hemoglobin concentration) were carried out in a Veterinary Hematology Analyzer (Exigo Eos Hematology System; Boule Diagnostics AB, Stockholm, Sweden). Plasma chemistry analyses were carried out in a clinical chemistry analyzer (Spin200E Automatic biochemistry analyzer; Spinreact, Barcelona, España). Creatine kinase (CK) was determined by the corresponding International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) method. Creatinine was determined by a kinetic modification of the Jaffe colorimetric method [16] and urea by a modification of the Talke and Schubert method [17]. Aspartate transaminase (AST) and alkaline phosphatase (ALP) were determined by the corresponding IFCC methods. Gamma-glutamyl transferase (GGT) was determined by a modification of the Szasz procedure [18]. Total protein concentration was determined by the Biuret method [19], and albumin concentration by the bromocresol green colorimetric method [20].

#### 2.5. Venom fractionation by FPLC

Fifteen milligrams of venoms of *D. polylepis* and *N. nigricollis* were fractionated by size exclusion chromatography in an AKTA

| Day | Venom (mg) | Injection volume (mL) |
|-----|------------|-----------------------|
| 1   | 0.5        | 2.0                   |
| 15  | 0.5        | 2.0                   |
| 20  | 0.5        | 2.0                   |
| 34  | 0.5        | 2.0                   |
| 43  | 1.0        | 2.0                   |
| 60  | 2.0        | 2.0                   |
| 71  | 3.0        | 2.0                   |
| 78  |            | Bleding               |

*In each group of horses, the same adjuvant was used throughout the immunization in all injections.*
FPLC system equipped with a Superdex 200 column. The flow rate was set to 1 mL/min and a mobile phase composed of 5 mM Tris-HCl, 150 mM NaCl, pH 7.5 was used for separation. Protein peaks detected at 280 nm were collected and stored at −20 °C until analysis.

2.6. Reactivity of equine sera by enzyme-linked immunosorbent assay (ELISA)

Determination of serum concentration of anti-venom antibodies was done in serum samples from each horse at different points during the immunization scheme. In some experiments, polystyrene plates were coated overnight at room temperature with 100 μL of PBS containing 3 μg of venom of either B. arietans, E. ocellatus, D. polylepis or N. nigricollis. In other experiments, plates were coated with 100 μL of PBS containing 32 μg or 7.5 μg of low molecular mass FPLC fractions (<30 kDa) of venoms of D. polylepis or N. nigricollis, respectively. After washing the plates five times with distilled water, 100 μL of 1:1000 dilution of sera from immunized horses, in PBS-2 % bovine serum albumin (BSA), were added. The plates were incubated for 1 h at room temperature and washed five times. Afterwards, 100 μL of goat anti-horse IgG conjugated with peroxidase, diluted 1:5000 with PBS-2 % BSA, were added to each well. Again, microplates were incubated for 1 h at room temperature. After a final washing step, color was developed by the addition of H2O2 and o-phenylenediamine. Color development was stopped by the addition of 1.0 M HCl. Absorbances at 492 nm were recorded. The relative concentration of anti-venom antibodies (percentage) in serum samples was calculated by interpolation of their absorbances in a calibration curve constructed by using a reference pool of hyperimmune equine plasma used for the commercial production of the antivenom EchiTab-plus-ICP. This hyperimmune plasma is generated by the immunization of horses with the four venoms used in this study. Results were expressed as average ± SD of all horses in each group.

2.7. Reactivity of equine sera by Western blot

Venoms of B. arietans, E. ocellatus, D. polylepis and N. nigricollis were separated in SDS-PAGE, under non-reducing conditions, using a 12 % acrylamide concentration [21]. Gels were transferred to a nitrocellulose membrane at 30 mAmp overnight. Then, the membranes were blocked with PBS-1 % casein for 30 min. Next, membranes were incubated for 1 h with a pool of serum samples of all horses in each group, diluted 1/1000 with PBS-0.1 % casein. After washing the membranes three times with PBS-2 % casein, they were incubated for 1 h with goat anti-horse IgG conjugated with peroxidase, diluted 1:2000 with PBS-0.1 % casein. Finally, after the last washing step, 4-chloro-1-naphthol color development substrate was added, and the reaction was stopped with distilled water. Families of the recognized bands were identified by comparing the electropherograms with those previously published for B. a. arietans [22], E. ocellatus [23], D. polylepis [24] and N. nigricollis [25].

2.8. Neutralization of lethal activity

Groups of five CD-1 mice were pretreated with tramadol s.c., at a dose of 50 mg/kg, to reduce pain during the test [26]. Fifteen minutes later, mice received an intravenous (i.v.) injection of 0.2 mL of solutions containing different mixtures of a challenge dose of venom with variable dilutions of a pool of antisera of horses from each group. Challenge doses corresponded to 5 LD50 for the venom of B. arietans and E. ocellatus, and 2 LD50 for the venom of D. polylepis and N. nigricollis. Saline solution was used as solvent for antisera dilutions. The mixtures were incubated at 37 °C for 30 min before injection. The number of deaths during the following 6 h were recorded [27] and used to estimate the median effective dose (ED50, i.e., the ratio mg venom/mL antiserum at which 50 % of the challenged mice survived) by Probits [28]. Surviving mice were euthanized by CO2 inhalation. Results were reported as ED50, expressed as mg venom per mL antiserum, and the corresponding 95 % confidence interval (95 % CI).

2.9. Statistical analyses

The plasma chemistry values were assessed by one-way ANOVA. For values of hematology parameters and antibody concentration, a general linear model of repeated measures test was used, and when the sphericity was not met, the Greenhouse-Geisser correction factor was used. A p-value < 0.05 was considered significant. In the case of the neutralization of the lethal activity, groups having non-overlapping values of the 95 % confidence intervals were considered significantly different.

3. Results and discussion

3.1. Clinical and laboratory alterations

Before immunization, all horses had an adequate health status, i.e., 370–490 kg body weight, horse body condition score between 5.5 and 6.5, normal hematology (Supplementary Table S1) and plasma chemistry parameters (Table 2), and no apparent clinical problems. Fourteen days after each immunogen injection, we observed the local lesions that developed at the site of immunogen injection.

Local lesions varied in size (from 0 to 20 cm diameter). We classified these lesions in three categories, depending on their pathological status (Fig. 1): Category 1 includes mild painful lesions (as judged by the reaction to palpation), characterized by a diffuse edema around the injection site, which are totally reabsorbed in the following 3–4 weeks. Category 2 includes well-circumscribed lesions associated with mild/moderate pain and characterized by the formation of soft consistency abscesses with thinned skin spots which eventually ulcerates and/or develops fistula through which a bloody pus-like material is discharged. These lesions develop scar tissue and heal in 4–8 weeks. Category 3 comprises well-circumscribed or diffused lesions associated with moderate/severe pain and characterized by the development of fibrous tissue (solid to palpation). These lesions may or may not involve fistula formation before fibrosis and are usually healed and reabsorbed in 4–10 weeks.

More abundant and severe local lesions developed in the horses immunized with Montanide, Freund, and Carbigenv adjuvants. These lesions were less frequent and severe in horses immunized with Emulsigen-D and almost absent in the horses immunized with QH-769 (Fig. 1). After the fourth booster, horse #171 had to be withdrawn from the study due to health problems not related to the immunization procedures. Therefore, the Emulsigen-D group has four missing observations (Fig. 1).

Tissue damage in the site of venom immunogen injection is likely to be due to a combination of a) the irritation of the surrounding tissue produced by the adjuvant, b) the toxic effects of the venom that is slowly released from the emulsion, and c) the activities triggered by inflammatory cells stimulated by venom and adjuvants [3]. However, our results suggest that the major contribution to the formation of local lesions is due to the adjuvants since the amount of venom was the same in all cases despite evident differences in the extent of local tissue damage depending on the adjuvant used.
Venoms of *Echis* spp have demonstrated their potential to induce local muscle damage during immunization in a rabbit model [29]. However, no significant increments in the plasma concentration of CK (F = 3.020 (1; 36), p = 0.091) were observed in these horse groups (Table 2), which indicates that the mass of venoms injected to horses in this study is not high enough to induce significant muscle damage. This result contrasts with a previous report in which higher doses (1.5–50.0 mg) of a mixture of venoms of *Bothrops asper*, *Crotalus simus*, *Lachesis stenophrys*, mixed with Freund or sodium alginate adjuvants, resulted in a small but significant rise of the plasma concentration of CK [30].

Systemic signs of envenomation (i.e., bleeding, hypotension, fever, hematuria, or neurotoxicity) were not observed in any of the groups. Moreover, no significant alterations of hematocrit (F = 1.608 (16.38; 57.38), p = 0.095) or hemoglobin (F = 1.568 (17.46; 61.12), p = 0.100) values, or erythrocyte (F = 1.759 (15.81; 55.35), p = 0.063), leukocyte (F = 1.064 (16.11; 56.41), p = 0.410) or platelet (F = 1.311 (11.89; 48.61), p = 0.236) counts were observed during immunization (Supplementary Table S1). Although significant differences in values of creatinine (F = 7.591 (1; 37), p = 0.009) and a slight variation in urea concentration (F = 4.230 (1; 37), p = 0.047) were observed (Table 2), the concentrations of these analytes were within the normal ranges of the local horse population (i.e., 61–150 μmol/L and 4–8 mmol/L, respectively), indicating that no kidney injury occurred during immunization. Moreover, when significant differences were observed, values at the end of immunization were generally lower than those before the immunization, hence indicating that no increments in these analytes occurred.

In contrast to our previous results obtained in a rabbit model [29], no evident hepatic damage was induced during the immunization. Despite the fact that AST plasma concentration showed a significant difference at the end of the immunization scheme
(F = 29.080 (1; 37), p < 0.0001) (Table 2), the upper limit of the normal interval for this enzyme (i.e., 449 IU/L) was not exceeded. Moreover, no significant changes in plasma concentration of ALP (F = 1.088 (1; 37), p = 0.304) and GGT (F = 1.026 (1; 36), p = 0.318) were observed during immunization (Table 2).

Overall, our observations indicate that, with the venom doses used in the immunization scheme, no systemic effects of envenomation developed in the immunized horses. The main impact of immunization in the horses’ health was related to the local tissue alterations, mostly due to the action of some adjuvants.

A significant increment in the total protein concentration in plasma was observed in horses immunized with Montanide (F = 16.194 (1; 6), p = 0.007), Freund (F = 23.088 (1; 6), p = 0.003) and Emulsigen-D (F = 58.435 (1; 6), p = 0.001) adjuvants. This finding is explained by a rise in the plasma concentration of globulins (F = 59.051 (1; 37), p < 0.0001) (particularly anti-venom immunoglobulins), which is partially compensated by a decrease of the plasma albumin concentration (F = 59.797 (1;37), p < 0.0001). A similar change in the globulin/albumin ratio has been described in previous studies in horses immunized with viperid snake venoms from Costa Rica [31].

### 3.2. Antibody response

Immunization of horses resulted in a gradual increase of the serum concentration of anti-venom immunoglobulins, as judged by ELISA. Montanide (F = 202.533 (1.7; 20.7), p < 0.0001) and Freund (F = 189.904 (1.4; 40.8), p < 0.0001) were the adjuvants with the highest ability to enhance the plasma concentration of anti-venom antibodies towards the four venoms. Carbigen (F = 33.537 (1.2; 15.2), p < 0.0001) showed an intermediate performance, while Emulsigen-D (F = 66.597 (2.1; 17.2), p < 0.0001) and QH-679 (F = 40.787 (1.3; 16.0), p < 0.0001) induced the lowest antibody titers (Fig. 2).

The five adjuvants tested induced an antibody response with a similar reactivity profile towards the four venoms, as judged by Western blot (Fig. 3). However, sera from horses immunized with Montanide or Freund adjuvants were those with the major ability to recognize some low molecular mass components. This was evidenced by a Western blot detecting antibodies towards whole venoms (Fig. 3) and an ELISA detecting antibodies towards the low molecular mass components (<30 kDa) in the venoms of *D. polylepis* and *N. nigricollis* (Fig. 4). This is relevant since PLA2s and low molecular mass cytotoxins of the 3FTx family are key components of *N. nigricollis* venom and play a role in the local dermonecrosis characteristic of envenomations by this species of spitting cobra [25,32].

In agreement with these immunochemical findings, the pools of sera of horses immunized with Montanide or Freund adjuvants were those with the highest ability to neutralize the lethal activity of all venoms (Fig. 5). However, as indicated by the overlapping of 95 % CIs, this tendency was significant only in some cases such as: Montanide or Freund versus QH-769 in the neutralization of *B. arietans* venom, Freund versus QH-769 in the neutralization of *E. ocellatus* venom, Montanide or Freund versus Carbigen, Emulsigen-D or QH-769 in the neutralization of *D. polylepis* venom, and Montanide versus Freund, Carbigen, Emulsigen-D or QH-769 in the neutralization of *N. nigricollis* venom (Fig. 5). Regardless of the differences between adjuvants, these results agree with the general trend that viperid venoms generate a higher immune response in horses as compared to elapid venoms.

The results obtained in this study agree with previous findings describing that Montanide and Freund are the adjuvants with the highest ability to enhance the antibody response of animals used
Fig. 3. Western blot analysis of the immunoreactivity profile against individual venoms of sera of horses immunized with a mixture of venoms of *B. arietans*, *E. ocellatus*, *D. polylepis*, and *N. nigricollis* emulsified in different adjuvants. Venoms correspond to A) *B. arietans*, B) *E. ocellatus*, C) *D. polylepis* and D) *N. nigricollis*. Antisera were obtained from horses immunized with 1) Montanide, 2) Freund, 3) Carbigen, 4) Emulsigen-D and 5) QH-769. Families of the recognized bands were identified by comparing the electropherograms with those previously published for *B. arietans* [23], *E. ocellatus* [24], *D. polylepis* [25] and *N. nigricollis* [26]. Molecular mass markers are depicted to the left.

Fig. 4. FPLC-chromatograms of venoms of *D. polylepis* (A) and *N. nigricollis* (B), and ELISA determination of the antibody response towards the fractions containing toxins with molecular mass lower that 30 kDa (marked with arrows) at the end of the immunization process (C). ELISA results are expressed as percentage, considering as 100 % the titer of a reference pool of hyperimmune equine sera used for the commercial production of the antivenom EchiTab-plus-ICP. Values correspond to the mean ± standard error (n = 4).
as immunoglobulin source for antivenom production [6–10,33]. However, since these adjuvants induce local damage at the site of injection, their use must be limited to the first stages of the immunization scheme [3]. It remains to be determined whether the low-dose, low-volume, multi-site protocol described for anti-venom generation by some authors [10] would reduce the extent of local tissue alterations induced by the emulsion-type adjuvants in horses.

4. Conclusions

Our comparative analysis of five emulsion-based adjuvants of different design and composition revealed differences in their ability to generate anti-venom antibody responses in horses as well as in the local tissue damage associated with immunization with venoms of four African snake species. The adjuvants that generated the highest immune response were Montanide and Freund, although they also induced local lesions at the site of injection, with no evidence of systemic alterations. In contrast, less tissue damage was induced by Emulsigen-D and QH-769, although the antibody response in horses receiving these adjuvants was lower. Carbigen induced local lesions similar to Montanide and Freund adjuvants and showed an intermediate ability to enhance the plasma concentration of anti-venom antibodies. Our results suggest that a possible combination of adjuvants aimed at generating a satisfactory immune response without having local deleterious effects could be based on the use of Montanide or Freund-based emulsions in the first immunization steps, followed by the use of Emulsigen-D, QH-769 or similar adjuvants in the following injections, a hypothesis that remains to be investigated.

Funding

This study was supported by Wellcome Trust [Reference 220517/Z/20/Z] awarded to GL and JMG, and Vicerrectoría de Investigación, Universidad de Costa Rica [projects 741-A0-804 and 741-C0-523].

Author Contributors

León G and Gutiérrez JM conceptualized and designed the study. Arguedas M, Umaña D, Moscoso E, García A, Pereira C, Sánchez A, Durán G, Cordero D, Sánchez A, Segura Á, Vargas M, Herrera M, Villalta M, Gómez A, Salas C and Díaz C acquired, analyzed and/or interpreted the data. León G drafted the original manuscript. Arguedas M, Umaña D, Moscoso E, García A, Pereira C, Sánchez A, Durán G, Cordero D, Sánchez A, Segura Á, Vargas M, Herrera M, Villalta M, Gómez A, Salas C, Díaz C and Gutiérrez JM reviewed the manuscript and made contributions to the intellectual content. All the authors approved the final version of the manuscript.

Data availability

No data was used for the research described in the article.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors thank Rodrigo Sánchez, Christian Vargas, Orlando Morales, and other colleagues at Instituto Clodomiro Picado for their collaboration.

Ethical statement

This manuscript presents an experimental study performed following the standard procedures of scientific ethics, including those related to the use and care of animals. All procedures involving animals were approved by the Institutional Committee for the Care and Use of Laboratory Animals of Universidad de Costa Rica (approval code CICUA 202-2020).

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jvacx.2022.100233.

References

[1] WHO (World Health Organization). WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins. Geneva:WHO; 2016.
[2] da Silva WD, Tambourgi DV. The humoral immune response induced by snake venom toxins. Inflamm Allergy Drug Targets 2011; 10(5):343-357. https://doi:10.2174/187152811797200623.
[3] León G, Sánchez L, Hernández A, Villalta M, Herrera M, Segura A, et al. Immune response towards snake venoms. Inflamm Allergy Drug Targets 2011; 10(5):381-398. https://doi:10.2174/187152811797200605.
[4] León G, Vargas M, Segura A, Herrera M, Villalta M, Sánchez A, et al. Current technology for the industrial manufacture of snake antivenoms. Toxicon 2018;151:63–73.
[5] Valverde JM, Rodríguez K, Herrera M, Segura A, Vargas M, Villalta M, et al. Comparison of the adjuvant activity of emulsions with different physicochemical properties on the antibody response towards the venom of West African carpet viper (Echis ocellatus). Toxicon 2017;127:106–11.
[6] Sunthornandh P, Ratanabanakangkoon K. A comparative study of three vehicles on antibody responses against elapid snake neurotoxin immunogens. Toxicon 1994;32(5):561–71.
[7] Pratanaphon R, Akesowan S, Khow O, Siriprapat S, Ratanabanakangkoon K. Production of highly potent horse antivenom against the Thai cobra (Naja naja). Vaccine 1997;15(14):1523–8.
[8] Waghmare AB, Deopurkar RL, Salvi N, Khadilkar M, Kalolikar M, Gade SK. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) alongwith incomplete Freund’s adjuvant for hyperimmunization of equines used for production of polyclonal snake antivenom. Vaccine 2005;23(17):1067–72.
[9] Waghmare AB, Salvi NC, Deopurkar RL, Shenoy PA, Sonpetkar JM. Evaluation of health status of horses immunized with snake venom and montanide adjuvants, IMS 3012 (nanoparticle), ISA 206 and ISA 35 (emulsion based)
during polyvalent snake antivenom production: Hematological and biochemical assessment. Toxicon 2014;82:83–92.

[10] Chotwiwatthanakun C, Pratanaphon R, Akesowan S, Sriprapat S, Ratanabanangkoon K. Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi-site immunization protocol. Toxicon 2001;39(10):1487–94.

[11] Brito LA, Malaya P, O’Hagan DT. Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol 2013;25(2):130–45.

[12] Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001;19(17-19):2666–72.

[13] Shen S-S, Yang Y-W. Antigen delivery for cross priming via the emulsion vaccine adjuvants. Vaccine 2012;30(9):1560–71.

[14] CIOMS (Council of International Organizations of Medical Sciences). The International Guiding Principles for Biomedical Research Involving Animals. Geneva: Z.Bankowski & N. Howard-Jones; 1986.

[15] Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score, physical measurements and body fat percentage in mares. Equine Vet J 1983; 15(4):371–372. https://doi: 10.1111/j.2042-3306.1983.tb01826.x.

[16] Mazzachi BC, Peake MJ, Ehrhardt V. Reference range and method comparison studies for enzymatic and Jaffé creatinine assays in plasma and serum and early morning urine. Clin Lab 2000;46(1–2):53–5.

[17] Talke H, Schubert GE. Enzymatic urea determination in the blood and serum in the Warburg optical test. Klin Wochenschr 1965; 43:174–175. https://doi:10.1007/BF01484513.

[18] Szasz G. A kinetic photometric method for serum γ-glutamyl transeptidase. Clin Chem 1969;15(2):124–36. https://doi.org/10.1093/clinchem/15.2.124.

[19] Cornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the Biüret reaction. J Biol Chem 1949;177:751–66.

[20] Rodkey FL. Direct spectrophotometric determination of albumin in human serum. Clin Chem 1965;11:478–87.

[21] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227(5259):680–5.

[22] Juárez P, Wagstaff SC, Oliver J, Sanz L, Harrison RA, Calvete JJ. Molecular cloning of disintegrin-like transcript BA-5A from a Bits arietans venom gland cDNA library: a putative intermediate in the evolution of the long-chain disintegrin bitistatin. J Mol Evol 2006;63(1):142–52.

[23] Wagstaff SC, Sanz L, Juárez P, Harrison RA, Calvete JJ. Combined snake venomics and venom gland transcriptomic analysis of the ocelated carpet viper Echis ocellatus. J Proteomics 2009;71(6):606–23.

[24] Lauratsen AH, Lomonte B, Lohse B, Fernández J, Gutiérrez JM. Unveiling the nature of black mamba (Dendroaspis polyaena) venom through venomics and antivenom immunoprofiling: identification of key toxin targets for antivenom development. J Proteomics 2015;119:126–42. https://doi.org/10.1016/j.jprot.2015.02.007.

[25] Petras D, Sanz L, Segura Á, Herrera M, Villalta M, Solano D, et al. Snake venomics of African spitting cobras: toxin composition and assessment of congeneric cross-reactivity of the pan-African EchisTab-Plus-ICP antivenom by antivenomics and neutralization approaches. J Proteome Res 2011;10(3):1266–80.

[26] Herrera C, Bolton F, Arias AS, Harrison RA, Gutiérrez JM. Analgesic effect of morphine and tramadol in standard toxicity assays in mice injected with venom of the snake Bothrops asper. Toxicon 2018;154:35–41.

[27] Durán G, Solano C, Gómez A, Cordero D, Sánchez A, Villalta M, et al. Assessing a 6-h endpoint observation time in the lethality neutralization assay used to evaluate the preclinical efficacy of snake antivenoms. Toxicon: X 2021;12:100087.

[28] Finney DJ. Probit Analysis. Cambridge: Cambridge University Press; 1971.

[29] Gómez A, Sánchez A, Durán G, Cordero D, Segura Á, Vargas M, et al. Intragenic cross-reactivity of monospecific rabbit antisera against venoms of the medically most important Bitsis spp. and Echis spp. African snakes. PLoS Negl Trop Dis 2022;16(8):e0010643.

[30] Angola Y, Estrada R, Gutiérrez JoséMaría. Clinical and laboratory alterations in horses during immunization with snake venoms for the production of polyvalent (Crotalinae) antivenom. Toxicon 1997;35(1):81–90.

[31] Estrada R, Robles A, Alvarado J, Rojas E, González N, Segura E, et al. Development of antibody response and clinical and hematological alterations in horses immunized with snake venoms for the production of antivenoms in Costa Rica. Mem Inst Butantan 1991;53:181–90.

[32] Rivel M, Solano D, Herrera M, Vargas M, Villalta M, Segura Á, et al. Pathogenesis of dermonecrosis induced by venom of the spitting cobra, Naja nigricollis: An experimental study in mice. Toxicon 2016;119:171–9.

[33] Freitas TV, Fortes-Dias CL, Diniz CR, Velarde DT, Freitas CF. Immunization of horses with Crotalidae venoms: a comparison of four different procedures. Braz J Med Biol Res 1991;24(3):281–90.